



Polyclonal Antibody against Human Cystatin C

Catalog Number: 11240

Size: 100 µg

Host: Rabbit

Immunogen:

Native protein isolated from human urine

Isotype/Preparation:

Rabbit crude IgG was purified by protein-G column

Specificity:

The antibody detects circular and uric human Cystatin C.

Formulation:

Solution in PBS.

Storage:

Store at -20°C. For long-term storage, aliquot and freeze at -70°C.
Avoid repeated freeze/thaw cycles.

Application/Usage:

ELISA - This antibody can be used at 2µg/mL with the appropriate secondary reagents to detect human Cystatin C.

Western blot, Immunoprecipitation and immunocytochemistry are not tested.

Introduction

Human cystatin C (or cystatin 3), which is composed of 120 amino acid residues, belongs to the cystatins superfamily that inactivates lysosomal cysteine proteinases. As a strongly cationic and low-molecular weight (13.4 kDa) protein, it is almost freely filtered across the glomerular membrane, and is mainly used as a biomarker of kidney function. A growing body of evidence suggests that cystatin C is a more reliable biomarker of glomerular filtration rate than creatinine [1-3].

In addition to kidney disease, altered serum levels of cystatin C are associated with several types of cardiovascular disease, including myocardial infarction, stroke, heart failure, peripheral arterial disease and metabolic syndrome [4-7]. It also seems to play a role in brain disorders involving amyloid, such as Alzheimer's disease [8, 9]. Furthermore, Cystatin C has also been investigated as a prognostic marker in several forms of cancer [11, 12].

Reference:

- [1] Stevens LA, Coresh J, Schmid CH, et al. (2008) *Am J Kidney Dis.* 51:395-406.
- [2] Dharnidharka VR, Kwon C, Stevens G. (2002) *Am. J. Kidney Dis.* 40 (2): 221-6.
- [3] Hermida J, Tutor JC. (2006) *Ther Drug Monit.* 28 (3): 326-31.
- [4] Zethelius B, Berglund L, Sundström J, et al. (2008) *N. Engl. J. Med.* 358 (20): 2107-16.
- [5] Ix JH, Shlipak MG, Chertow GM, Whooley MA. (2007) *Circulation* 115 (2): 173-9.
- [6] Deo R, Fyr CL, Fried LF, et al. (January 2008) *Am. Heart J.* 155 (1): 62-8.
- [7] Servais A, Giral P, Bernard M, et al. (2008) *Am. J. Med.* 121 (5): 426-32.
- [8] Mi W, Pawlik M, Sastre M, et al. (2007) *Nat. Genet.* 39 (12): 1440-2.
- [9] Kaeser SA, Herzig MC, Coomaraswamy J, et al. (2007) *Nat. Genet.* 39 (12): 1437-9.
- [10] Zurdel J, Finckh U, Menzer G, et al. (2002) *Br J Ophthalmol* 86 (2): 214-9.
- [11] Stojan P, Oblak I, Svetic B, et al. (2004) *Br. J. Cancer* 90 (10): 1961-8.
- [12] Kos J, Krasovec M, Cimernan N, et al. (2000) *Clin. Cancer Res.* 6 (2): 505-11.